Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations

ABSTRACT Background Anaplastic lymphoma kinase (ALK) rearrangements are rare in non‐myofibroblastic sarcoma and there is limited data on the efficacy of ALK tyrosine kinase inhibitors (TKIs) and mechanisms of resistance in these patients. Case A 58 year‐old man with metastatic non‐myofibroblastic sa...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Isabella Wilson, Min Qiu, Malinda Itchins, Bin Wang, Min Li Huang, Peter Grimison
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2024-08-01
Serie:	Cancer Reports
Soggetti:	alectinib anaplastic lymphoma kinase lorlatinib sarcoma tyrosine kinase inhibitors
Accesso online:	https://doi.org/10.1002/cnr2.2164
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!